Greater Occipital Nerve Block Alone Versus Dual Nerve Block in Cervicogenic Headache and Occipital Neuralgia

NCT ID: NCT07068451

Last Updated: 2025-07-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-01

Study Completion Date

2023-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study looked at two types of nerve block injections used to treat people with cervicogenic headache (CEH) and occipital neuralgia (ON)-two painful conditions that often cause pain at the back of the head and neck. The injections target nerves in the upper neck that may be causing the pain.

The researchers compared:

One nerve injection (greater occipital nerve block, or GONB), versus

Two nerve injections (GONB plus lesser occipital nerve block, or LONB).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ervicogenic Headache (CEH) Occipital Neuralgia (ON)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GONB Alone

Patients received a single injection of 1 mL of 2% lidocaine at the greater occipital nerve using a landmark-guided technique.

Group Type EXPERIMENTAL

Greater Occipital Nerve Block (GONB)

Intervention Type PROCEDURE

A landmark-guided injection of 1 mL of 2% lidocaine administered at the anatomical location of the greater occipital nerve (GON) to treat cervicogenic headache and occipital neuralgia. Performed without corticosteroids or imaging guidance.

GONB + LONB (Dual Block)

Patients receive two injections of 1 mL of 2% lidocaine each at the greater and lesser occipital nerves using a landmark-guided technique.

Group Type EXPERIMENTAL

Combined Greater and Lesser Occipital Nerve Block (GONB + LONB)

Intervention Type PROCEDURE

Two landmark-guided injections of 1 mL of 2% lidocaine each at the anatomical locations of the greater and lesser occipital nerves. Performed without corticosteroids or imaging, targeting broader nerve involvement in cervicogenic headache and occipital neuralgia.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Greater Occipital Nerve Block (GONB)

A landmark-guided injection of 1 mL of 2% lidocaine administered at the anatomical location of the greater occipital nerve (GON) to treat cervicogenic headache and occipital neuralgia. Performed without corticosteroids or imaging guidance.

Intervention Type PROCEDURE

Combined Greater and Lesser Occipital Nerve Block (GONB + LONB)

Two landmark-guided injections of 1 mL of 2% lidocaine each at the anatomical locations of the greater and lesser occipital nerves. Performed without corticosteroids or imaging, targeting broader nerve involvement in cervicogenic headache and occipital neuralgia.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Drug: Lidocaine 2% Drug: Lidocaine 2%

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

Previous nerve block or other interventional procedures for headache

Use of systemic corticosteroids within the past 3 months

Known allergy to lidocaine or other amide-type local anesthetics

Evidence of secondary causes of headache on imaging (e.g., tumor, infection)

Pregnancy or breastfeeding

Active infection at the injection site

Coagulopathy or use of anticoagulant therapy

Significant psychiatric or neurological comorbidities interfering with study participation
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tishreen University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ali Hammed

Dr

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Latakia

Latakia, , Syria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Syria

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

N/2020-31

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Predictors of GON Blockade Success in Migraine
NCT07170111 NOT_YET_RECRUITING NA